现代医药卫生2023，Vol.39Issue(24)：4261-4265,5.DOI:10.3969/j.issn.1009-5519.2023.24.025
脂蛋白(a)与心血管疾病风险的研究进展
Research progress of lipoprotein(a)with cardiovascular risk
叶青 1史微 2杨明 2李军 2李琼芬2
作者信息
- 1. 云南省滇南中心医院(红河州第一人民医院)心血管内科,云南红河 661000
- 2. 云南省滇南中心医院(红河州第一人民医院)医学检验科,云南红河 661000
- 折叠
摘要
Abstract
There is a significant correlation that the elevation of lipoprotein(a)[Lp(a)]levels is associ-ated with the occurrence of cardiovascular disease(CVD),and this recognition has gradually gained attention.However,evidence on effective ways to lower Lp(a)and whether lowering Lp(a)levels improves cardiovascu-lar disease risk remains insufficient,resulting in the importance of Lp(a)not being fully recognized yet.The latest clinical and genetic research progress reveal the key role of Lp(a)in the pathogenesis of CVD.There-fore,emerging therapeutic strategies,such as proprotein convertase bacillus subtilis protease-kexin type 9 in-hibitors or antisense oligonucleotide technology,show some potential in lowering Lp(a).This article reviewed the research progress of Lp(a)and cardiovascular risk.关键词
脂蛋白(a)/心血管疾病/药物代谢/载脂蛋白AKey words
Lipoprotein(a)/Cardiovascular disease/Drug metabolism/Apolipoprotein A分类
医药卫生引用本文复制引用
叶青,史微,杨明,李军,李琼芬..脂蛋白(a)与心血管疾病风险的研究进展[J].现代医药卫生,2023,39(24):4261-4265,5.
